Barinib 4 ( Baricitinib 4mg)

Baricitinib 4mg (generic) is a Janus kinase (JAK) inhibitor used to treat adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. It is a cost-effective alternative to Olumiant, offering similar therapeutic benefits at a significantly lower price.

Indications

Baricitinib 4mg is indicated for:

• Moderate to severe rheumatoid arthritis in adults

• Patients who did not respond adequately to TNF inhibitors

Limitations of Use

Baricitinib should not be used in combination with:

• Other JAK inhibitors

• Biologic DMARDs

• Potent immunosuppressants (e.g., azathioprine, cyclosporine)

Dosage Guidelines

• Recommended dose: 4 mg once daily

• Can be used:

  • As monotherapy
  • Or in combination with methotrexate or other DMARDs

Precautions

Before starting treatment, monitor the following:

• Anemia: Avoid use if hemoglobin < 8 g/dL

• Lymphopenia: Avoid use if ALC < 500 cells/mm³

• Neutropenia: Avoid use if ANC < 1000 cells/mm³

Side Effects

Common side effects may include:

• Upper respiratory tract infections (e.g., cold, sinus infections)

• Herpes infections (cold sores, shingles)

• Nausea

Price Advantage

Generic Baricitinib 4mg is typically available at up to 80–90% lower cost compared to branded Olumiant in the USA and other markets, making it an affordable treatment option for long-term therapy.

Prescribing Information

For full prescribing details, refer to official FDA prescribing information or consult a licensed healthcare provider before use.